Pharmaceutical Technology·· 7 days agoPickScore81
FDA approves Asahi Kasei’s Hovilpri for refractory HSV
In brief
The US FDA has approved Asahi Kasei Therapeutics' Hovilpri (pritelivir) 100mg tablets for refractory mucocutaneous HSV lesions in immunocompromised adults who do not respond to standard antiviral treatments such as acyclovir, famciclovir, or valacyclovir.
Why it matters
The article gives specific day-28 and day-42 complete healing and safety differences, and compares Hovilpri's helicase-primase mechanism with nucleoside analogues.
Source: Pharmaceutical Technology · pharmaceutical-technology.com